Department of Dermatology, the Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Clinical Lab, the Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Chin J Integr Med. 2021 Apr;27(4):286-290. doi: 10.1007/s11655-020-3075-x. Epub 2020 May 15.
To evaluate the effect and safety of cinnamaldehyde on immunosuppressed mice with invasive pulmonary candidiasis.
An immunosuppressed BALB/c mouse model was established by intraperitoneal administration of cyclophosphamide (200 mg/kg) once daily for 2 days. The immunosuppressed mouse with invasive pulmonary candidiasis model was further established by nasal perfusion of Candida albicans suspension. In the cinnamaldehyde treatment group, immunosuppressed mice with invasive pulmonary candidiasis were orally given cinnamaldehyde 240 mg/(kg·d) for 14 consecutive days. Fluconazole and 0.9% saline were used as the positive and negative controls, respectively. The mice in the cinnamaldehyde safety evaluation group were orally administered cinnamaldehyde 480 mg/(kg·d) for 42 days to observe the safety of the drug. Microscopic identification, fungal culture, histopathological examination, and (1,3)-beta-D-glucans detection were conducted to analyze the effect of cinnamaldehyde on C. albicans.
The fungal clearance rate in the cinnamaldehyde treatment group was higher than that in the fluconazole control group (80.00% vs. 56.67%, P<0.05). The level of (1,3)-β-D-glucan in the cinnamaldehyde treatment group was lower than that in the fluconazole positive control group (1160.62 ±89.65 pg/mL vs. 4285.87 ± 215.62 pg/mL, P<0.05). The survival rate of mice in the cinnamaldehyde safety evaluation group was 100%, and no significant pathological changes of kidney, lung and liver were observed.
Cinnamaldehyde was effective and safe in treating immunosuppressed BALB/c mice with invasive pulmonary candidiasis. It would be a potentially novel drug for anti-candidiasis infection.
评估肉桂醛对免疫抑制侵袭性肺念珠菌病小鼠的作用和安全性。
采用腹腔注射环磷酰胺（200mg/kg），每天 1 次，连续 2 天，建立 BALB/c 小鼠免疫抑制模型；再经鼻腔灌注白色念珠菌混悬液，建立侵袭性肺念珠菌病模型。肉桂醛治疗组给予免疫抑制侵袭性肺念珠菌病小鼠肉桂醛 240mg/（kg·d）灌胃，连续 14 天；氟康唑和 0.9%生理盐水分别作为阳性对照和阴性对照。肉桂醛安全性评价组给予免疫抑制侵袭性肺念珠菌病小鼠肉桂醛 480mg/（kg·d）灌胃，连续 42 天，观察药物安全性。通过显微镜检查、真菌培养、组织病理学检查和（1,3）-β-D-葡聚糖检测，分析肉桂醛对白色念珠菌的作用。
肉桂醛治疗组的真菌清除率高于氟康唑对照组（80.00%比 56.67%，P<0.05）。肉桂醛治疗组（1,3）-β-D-葡聚糖水平低于氟康唑阳性对照组（1160.62±89.65pg/ml 比 4285.87±215.62pg/ml，P<0.05）。肉桂醛安全性评价组小鼠的存活率为 100%，肾脏、肺和肝脏未见明显病理变化。
肉桂醛对免疫抑制 BALB/c 小鼠侵袭性肺念珠菌病有效且安全，可能成为一种新型抗念珠菌感染药物。
